This article first appeared on GuruFocus .
Release Date: July 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
WVE-007 demonstrated robust and durable silencing of INHBE in Phase 1, supporting potential for once or twice yearly dosing in obesity.
-
WVE-007 showed substantial reductions in visceral fat and subcutaneous fat without muscle loss, a key differentiator from incretin therapies.
-
WVE-006 for AATD achieved a compelling therapeutic profile, including ZAAT reduction and dynamic AAT response, positioning it for a potential accelerated approval pathway.
-
WAVE is advancing a second RNA editing candidate, WVE-008, for PNPLA3 liver disease, targeting a high unmet need with strong human genetic support.
-
The company has a strong cash position of $490.6 million, expected to fund operations into Q3 2028, supporting pipeline advancement.
Negative Points
-
Net loss increased significantly to $69.4 million in Q2 2026 from $15.5 million in Q2 2025, driven by higher R&D and G&A expenses.
-
Revenue declined to $2.3 million in Q2 2026 from $8.7 million in the prior year quarter, reflecting lower collaboration income.
-
WVE-007's Phase 2a trial is still early, and the magnitude of weight loss and fat reduction in higher BMI patients remains to be confirmed.
-
The regulatory pathway for WVE-006 is still under discussion, with an FDA meeting planned for late summer, creating uncertainty on timelines.
-
The company is seeking partnerships for its HD and DMD programs, indicating a strategic shift and potential challenges in advancing these assets independently.
Q & A Highlights
Q: For the ongoing Phase 2A portion of the INLITE trial for WVE-007 in obesity, is the goal to confirm 5% weight loss vs. placebo at 12 months to support advancement? And for combination therapy, what are your expectations and potential differentiation? A: Paul Bono, President and CEO: The Phase 2A is designed to cross the regulatory threshold of 5% weight loss. We expect to see weight loss in this higher BMI population, similar to how other therapies like tirzepatide showed greater than 5% weight loss in similar settings. For combination therapy, we believe our preclinical data showing about threefold more potency positions us well. We are also excited about the maintenance setting as a key differentiator, where our data shows potential to curtail weight regain after incretin cessation.
Q: In the Phase 2A INLITE trial, what metrics are you focused on, and what magnitude of improvement is needed to support expansion into MASH or type 2 diabetes? A: Chris Wright, Chief Medical Officer: We are looking at MRI-PDFF to measure liver fat, which is highly competitive with other compounds in the MASH space. We will also be evaluating hemoglobin A1C. The study is designed to unlock broader cardiometabolic opportunities beyond just obesity.
Q: Can you provide more detail on the Phase 1 data for WVE-007, specifically the visceral fat to muscle ratio (VMR) and how it compares to other therapies? A: Eric Engelson, Chief Scientific Officer: With a single dose of WVE-007 in Phase 1, we observed a 16.5% improvement in VMR. This compares favorably to the 12.2% achieved with weekly semaglutide in the Phase 2 BELIEVE study and approaches the 18.8% seen with tirzepatide. This is particularly notable because our Phase 1 participants had substantially lower baseline BMI and visceral fat, where effects are typically more modest.
Q: What is the status of the FDA meeting for WVE-006 in AATD, and what is the potential for an accelerated approval pathway? A: Paul Bono, President and CEO: The FDA has granted our request for a meeting, which is expected at the end of summer. We intend to discuss a potential accelerated approval pathway for WVE-006 in AATD. The feedback will help inform our registrational plans and path toward bringing a new treatment option to the 200,000 individuals in the U.S. and Europe living with homozygous ZZ AATD.
Q: What is the therapeutic profile of WVE-006 that you have observed so far, and how does it compare to the MZ-like phenotype you are targeting? A: Chris Wright, Chief Medical Officer: After three months of treatment, WVE-006 consistently delivered a compelling profile: ZAAT reduction, protective basal levels of wild-type MAAT above 11 micromolar, and a preserved acute phase response. This recapitulates the MZ-like phenotype, which is associated with low risk of both lung and liver disease. Importantly, the RNA editing approach produces only wild-type canonical MAAT, avoiding bystander edited isoforms seen with DNA editing.
Q: Can you provide an update on the progress of WVE-008 for PNPLA3 liver disease and its differentiation from silencing approaches? A: Chris Wright, Chief Medical Officer: We remain on track for a CTA submission in 2026. WVE-008 aims to correct the I148M variant using RNA editing, which is expected to restore PNPLA3 activity and reverse steatosis and fibrosis. This is differentiated from silencing approaches, which recent clinical trials have shown may exacerbate inflammation and fibrosis, as they knock down all PNPLA3 protein without restoring healthy wild-type function.
Q: What are the key financial highlights for the second quarter of 2026, and what is the cash runway? A: Kyle Moran, Chief Financial Officer: Revenue was $2.3 million, R&D expenses were $51.3 million, and G&A expenses were $24.8 million. Net loss was $69.4 million. We ended the quarter with $490.6 million in cash, which we expect to fund operations into Q3 2028. Potential future milestones from GSK are not included in this runway.
Q: What are the next steps for the DMD and HD programs, and are you still seeking partnerships? A: Paul Bono, President and CEO: Given the evolving regulatory and commercial landscape in DMD, we are exploring potential partnerships in advance of filing an NDA for WVE-N531. We continue to believe in the potential of WVE-N531 and WVE-N003 as best-in-class treatment options and look forward to continuing partnering discussions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
